Decitabine regulates the resistance of HCC to sorafenib through demethylation

Decitabine regulates the resistance of HCC to sorafenib through demethylation

Abstract Purpose To evaluate the efficacy of sorafenib in combination with the DNA methylation inhibitor decitabine (DAC) for the treatment of hepatocellular carcinoma (HCC), and to investigate the mechanism of sorafenib resistance from an epigenetic perspective, aiming to provide new insights and s...

Full description

Saved in:
Bibliographic Details
Main Authors: Miao Zhang, Xiaolei Zhou, Zhenzhen Li, TianYu Zhao, Yu Miao, Sen Liu, Qiaoqiao Han, Libo Wang, Yongdeng Xu, Tao Cui, Ze Wang, Xiulin Yi, Fengying Yan, Xiaoliang Wang
Format: Article
Language:English
Published: BMC 2025-07-01
Series:Clinical Epigenetics
Subjects:
DNA methylation
Decitabine
Sorafenib
OATP1B3
Hepatocellular carcinoma
Online Access:https://doi.org/10.1186/s13148-025-01925-w
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s13148-025-01925-w

Similar Items